NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

NVCT

Nuvectis Pharma Inc

Jul 14 • 04:00PM ET

8.22

Dollar change +0.34
Percentage change 4.31	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX AMGN GILD BMY REGN BIIB MRNA ILMN INCY NBIX

| Held by: VTI IWM VXF IWO IWC GSSC RSSL UWM URTY ITWO

Index	RUT	P/E	-	EPS (ttm)	-1.09	Insider Own	49.52%	Shs Outstand	23.63M	Perf Week	4.71%
Market Cap	171.74M	Forward P/E	-	EPS next Y	-1.07	Insider Trans	3.27%	Shs Float	10.55M	Perf Month	-6.91%
Enterprise Value	141.88M	PEG	-	EPS next Q	-0.25	Inst Own	9.82%	Short Float	25.03%	Perf Quarter	-3.58%
Income	-20.16M	P/S	-	EPS this Y	6.46%	Inst Trans	65.77%	Short Ratio	17.32	Perf Half Y	33.23%
Sales	0.00M	P/B	9.27	EPS next Y	-3.21%	ROA	-80.87%	Short Interest	2.64M	Perf YTD	51.94%
Book/sh	0.89	P/C	5.75	EPS next 5Y	9.24%	ROE	-115.28%	52W High	11.80 -30.34%	Perf Year	31.52%
Cash/sh	1.43	P/FCF	-	EPS past 3/5Y	-3.09% -510.36%	ROIC	-96.22%	52W Low	4.44 85.14%	Perf 3Y	-36.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.69% 5.78%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	20.56%	Oper. Margin	-	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.28	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.77	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.28	EPS Q/Q	-6.15%	SMA20	4.10%	Beta	-0.26	Target Price	19.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.94%	Rel Volume	1.32	Prev Close	7.88
Employees	13	LT Debt/Eq	0.00	Earnings	May 06 BMO	SMA200	9.86%	Avg Volume	152.49K	Price	8.22
IPO	Feb 04, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.30% -	Trades		Volume	201,162	Change	4.31%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Initiated	Maxim Group	Buy	$17
Mar-17-25	Initiated	Laidlaw	Buy	$19
Jul-13-22	Initiated	Ladenburg Thalmann	Buy	$21

Jul-08-25 08:00AM	Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies (GlobeNewswire)
May-16-25 04:35PM	Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +6.36% +10.94%
May-09-25 09:55AM	Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? (Zacks)
May-06-25 08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-25 05:28AM	Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 (Insider Monkey)
04:25PM	Loading…
Apr-29-25 04:25PM	Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting (GlobeNewswire)
Mar-26-25 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting (GlobeNewswire)
Mar-14-25 08:00AM	Nuvectis Pharma to Participate in the 37th Annual Roth Conference (GlobeNewswire) +5.99%
Mar-05-25 08:44AM	Market News Alert: Nuvectis Pharmas NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation (Business Wire)
Mar-04-25 08:00AM	Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC (GlobeNewswire)
Feb-27-25 10:43AM	Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets (Business Wire)
Feb-25-25 08:00AM	Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights (GlobeNewswire) -5.84%
Feb-07-25 08:30AM	Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option (GlobeNewswire) -7.32%
Feb-05-25 09:01AM	Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock (GlobeNewswire)
Feb-04-25 04:05PM	Nuvectis Pharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Loading…
Dec-10-24 08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium (GlobeNewswire)
Nov-25-24 09:55AM	Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-15-24 07:45AM	Nuvectis Pharma reports data from Phase 1b study of NXP800 (TipRanks) -13.61%
Nov-14-24 02:23PM	Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug (Benzinga) -46.30%
07:00AM	Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire)
Nov-13-24 08:50AM	Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-07-24 09:55AM	Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know (Zacks)
Nov-05-24 07:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +17.75%
Oct-28-24 08:21AM	PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update (Business Wire) -10.50%
Oct-23-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.33%
Oct-07-24 08:00AM	Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-16-24 07:15AM	PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch (Business Wire)
Sep-05-24 08:00AM	Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.81%
Aug-30-24 06:52AM	Nuvectis NXP800 gains FDA ODD for cancer treatment (Pharmaceutical Technology)
08:00AM	Loading…
Aug-29-24 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers (GlobeNewswire)
Aug-06-24 08:28AM	Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.83%
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace) +5.96%
May-24-24 09:55AM	Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? (Zacks) -7.04%
May-16-24 08:30AM	Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-07-24 09:06PM	Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes (GuruFocus.com) -10.57%
01:53PM	NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-08-24 08:30AM	Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines (GlobeNewswire)
Apr-02-24 04:30PM	5 Healthcare Stocks to Buy for 2024 (InvestorPlace)
Mar-19-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting (GlobeNewswire) -16.08%
Mar-15-24 08:00AM	Nuvectis Pharma to Present at the 36th Annual Roth Conference (GlobeNewswire) +20.22%
Mar-14-24 09:00AM	Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire) -5.08%
Mar-05-24 11:52PM	NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023 (InvestorPlace)
08:31AM	Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-09-24 08:32AM	Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-03-24 08:00AM	Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:00AM	Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma (GlobeNewswire)
Nov-08-23 08:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -7.83%
Oct-24-23 08:00AM	Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (GlobeNewswire)
Oct-16-23 09:35AM	Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT) (Zacks) +15.87%
Sep-25-23 07:30PM	Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation (GlobeNewswire)
Sep-21-23 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 (GlobeNewswire)
Sep-12-23 08:00AM	Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial (GlobeNewswire)
Sep-06-23 08:00AM	Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 (GlobeNewswire)
Sep-01-23 08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma (GlobeNewswire)
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
Aug-10-23 06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research)
Aug-09-23 08:00AM	Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research)
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research)
Aug-02-23 07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research) +7.41%
Aug-01-23 06:51AM	Daily Vickers Top Insider Picks for 08/01/2023 (Argus Research)
06:51AM	Daily Vickers Top Buyers & Sellers for 08/01/2023 (Argus Research)
Jul-31-23 06:44AM	Daily Vickers Top Insider Picks for 07/31/2023 (Argus Research)
Jul-28-23 07:58AM	Daily Vickers Top Insider Picks for 07/28/2023 (Argus Research)
07:58AM	Daily Vickers Top Buyers & Sellers for 07/28/2023 (Argus Research)
Jul-27-23 07:10AM	Daily Vickers Top Insider Picks for 07/27/2023 (Argus Research)
Jul-26-23 01:12PM	Daily Vickers Top Insider Picks for 07/26/2023 (Argus Research)
Jul-25-23 07:16AM	Daily Vickers Top Insider Picks for 07/25/2023 (Argus Research)
07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
Jul-24-23 07:12AM	Daily Vickers Top Insider Picks for 07/24/2023 (Argus Research)
Jul-21-23 07:23AM	Daily Vickers Top Insider Picks for 07/21/2023 (Argus Research) +5.18%
07:23AM	Daily Vickers Top Buyers & Sellers for 07/21/2023 (Argus Research)
Jul-20-23 06:55AM	Daily Vickers Top Insider Picks for 07/20/2023 (Argus Research)
06:55AM	Daily Vickers Top Buyers & Sellers for 07/20/2023 (Argus Research)
Jul-19-23 07:10AM	Daily Vickers Top Insider Picks for 07/19/2023 (Argus Research)
07:10AM	Daily Vickers Top Buyers & Sellers for 07/19/2023 (Argus Research)
Jul-18-23 06:53AM	Daily Vickers Top Insider Picks for 07/18/2023 (Argus Research)
Jul-17-23 07:10AM	Daily Vickers Top Insider Picks for 07/17/2023 (Argus Research)
Jul-14-23 06:50AM	Daily Vickers Top Insider Picks for 07/14/2023 (Argus Research)
06:50AM	Daily Vickers Top Buyers & Sellers for 07/14/2023 (Argus Research)
Jul-13-23 07:02AM	Daily Vickers Top Insider Picks for 07/13/2023 (Argus Research)
07:02AM	Daily Vickers Top Buyers & Sellers for 07/13/2023 (Argus Research)
Jul-12-23 07:22AM	Daily Vickers Top Insider Picks for 07/12/2023 (Argus Research)
Jul-11-23 06:08AM	Daily Vickers Top Insider Picks for 07/11/2023 (Argus Research)
06:08AM	Daily Vickers Top Buyers & Sellers for 07/11/2023 (Argus Research)
Jul-10-23 06:56AM	Daily Vickers Top Insider Picks for 07/10/2023 (Argus Research) +5.97%
06:56AM	Daily Vickers Top Buyers & Sellers for 07/10/2023 (Argus Research)
Jul-05-23 06:46AM	Daily Vickers Top Insider Picks for 07/05/2023 (Argus Research)
Jul-03-23 06:50AM	Daily Vickers Top Insider Picks for 07/03/2023 (Argus Research)
Jun-30-23 06:52AM	Daily Vickers Top Insider Picks for 06/30/2023 (Argus Research)
Jun-29-23 06:49AM	Daily Vickers Top Insider Picks for 06/29/2023 (Argus Research)
Jun-28-23 07:13AM	Daily Vickers Top Buyers & Sellers for 06/28/2023 (Argus Research)

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mosseri Marlio Charles	10% Owner	Jun 20 '25	Buy	7.99	5,603	44,768	2,981,806	Jun 24 05:14 PM
Mosseri Marlio Charles	10% Owner	Jun 18 '25	Buy	8.05	28,043	225,746	2,976,203	Jun 20 09:50 AM
Mosseri Marlio Charles	10% Owner	Jun 17 '25	Buy	8.11	5,399	43,786	2,948,160	Jun 20 09:50 AM
Mosseri Marlio Charles	10% Owner	May 12 '25	Buy	8.11	21,167	171,664	2,942,761	May 13 06:36 PM
Mosseri Marlio Charles	10% Owner	May 06 '25	Buy	8.59	12,444	106,955	2,896,565	May 09 06:53 PM
Mosseri Marlio Charles	10% Owner	May 07 '25	Buy	8.59	12,317	105,770	2,908,882	May 09 06:53 PM
Mosseri Marlio Charles	10% Owner	May 08 '25	Buy	8.65	2,650	22,922	2,911,532	May 09 06:53 PM
Mosseri Marlio Charles	10% Owner	Feb 07 '25	Buy	5.00	240,000	1,200,000	2,884,121	Feb 11 05:58 PM
BENTSUR RON	Chairman & CEO	Dec 24 '24	Buy	4.65	4,500	20,925	3,270,924	Dec 26 08:00 AM
Mosseri Marlio Charles	10% Owner	Dec 13 '24	Buy	4.70	17,000	79,900	2,612,000	Dec 16 08:00 AM
Poradosu Enrique	Chief Science & Business Off	Nov 19 '24	Buy	4.99	2,000	9,980	1,506,319	Nov 20 08:30 AM
BENTSUR RON	Chairman & CEO	Nov 15 '24	Buy	4.92	20,000	98,400	3,266,424	Nov 18 08:30 AM
Carson Michael J.	Vice President, Finance	Nov 07 '24	Sale	8.16	2,755	22,478	87,918	Nov 08 03:59 PM

Open in Screener

XAIR

Beyond Air Inc

Jul 14 • 04:00PM ET

3.05

Dollar change -0.40
Percentage change -11.65	%

Healthcare • Medical Devices • USA • NASD

Peers: MDT ABT ISRG SYK BSX EW INSP PEN NVCR TMDX

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-15.73	Insider Own	12.88%	Shs Outstand	4.13M	Perf Week	-19.65%
Market Cap	14.15M	Forward P/E	-	EPS next Y	-3.30	Insider Trans	9.19%	Shs Float	4.04M	Perf Month	-23.75%
Enterprise Value	19.45M	PEG	-	EPS next Q	-1.45	Inst Own	20.72%	Short Float	7.72%	Perf Quarter	-33.70%
Income	-46.63M	P/S	3.82	EPS this Y	63.04%	Inst Trans	25.23%	Short Ratio	1.85	Perf Half Y	-59.87%
Sales	3.71M	P/B	0.93	EPS next Y	35.29%	ROA	-107.16%	Short Interest	0.31M	Perf YTD	-57.46%
Book/sh	3.29	P/C	1.98	EPS next 5Y	-	ROE	-241.40%	52W High	13.52 -77.44%	Perf Year	-74.43%
Cash/sh	1.54	P/FCF	-	EPS past 3/5Y	25.75% 17.29%	ROIC	-192.15%	52W Low	3.04 0.26%	Perf 3Y	-98.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 21.66%	Gross Margin	-44.89%	Volatility	14.78% 14.93%	Perf 5Y	-97.78%
Dividend TTM	-	EV/Sales	5.24	EPS Y/Y TTM	56.69%	Oper. Margin	-1202.11%	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.72	Sales Y/Y TTM	219.67%	Profit Margin	-1258.46%	RSI (14)	40.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.20	EPS Q/Q	75.00%	SMA20	-19.31%	Beta	0.26	Target Price	45.00
Payout	-	Debt/Eq	0.86	Sales Q/Q	145.11%	SMA50	-19.72%	Rel Volume	1.65	Prev Close	3.45
Employees	61	LT Debt/Eq	0.79	Earnings	Jun 17 AMC	SMA200	-53.22%	Avg Volume	168.50K	Price	3.05
IPO	Sep 23, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.23% -16.42%	Trades		Volume	277,807	Change	-11.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-25-24	Downgrade	BTIG Research	Buy → Neutral
Jul-28-23	Initiated	Piper Sandler	Overweight	$10
Jun-15-23	Initiated	BTIG Research	Buy	$15
Apr-28-21	Initiated	Truist	Buy	$12
Oct-22-19	Initiated	Oppenheimer	Outperform	$9

Jun-26-25 09:55AM	Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher (Zacks) -6.47%
Jun-18-25 03:01AM	Beyond Air Inc (XAIR) (Q4 2025) Earnings Call Highlights: Revenue Soars Amidst Strategic Global ... (GuruFocus.com) -29.02%
Jun-17-25 05:15PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +58.69%
04:01PM	Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-16-25 09:16AM	Beyond Air Inc (XAIR) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	Loading…
08:00AM	Beyond Air Submits FDA PMA Supplement for Next Generation LungFit PH (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
May-28-25 05:20PM	Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-20-25 08:00AM	Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-24-25 04:05PM	Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) (GlobeNewswire)
Apr-21-25 04:05PM	NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism (GlobeNewswire)
Apr-15-25 04:05PM	NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board (GlobeNewswire)
Apr-09-25 04:05PM	Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit GO at Home (GlobeNewswire) +11.63%
Apr-01-25 08:00AM	NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders (GlobeNewswire) -8.22%
Mar-31-25 08:00AM	Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site (GlobeNewswire)
04:05PM	Loading…
Mar-24-25 04:05PM	NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy (GlobeNewswire) +5.63%
Mar-23-25 08:38AM	Beyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-11-25 07:30AM	Beyond Air Announces Agreements Expanding Global Distribution of LungFit PH (GlobeNewswire)
Mar-06-25 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -6.06%
Feb-10-25 04:05PM	Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.37% -6.49%
Feb-07-25 07:10AM	Beyond Air Inc (XAIR) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-05-25 09:29AM	Beyond Air Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Jan-27-25 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) -7.83%
Jan-24-25 09:15AM	Beyond Air Announces LungFit PH Receives Market Authorization in Australia (GlobeNewswire)
Jan-06-25 08:00AM	Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (GlobeNewswire)
Dec-03-24 04:05PM	Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy (GlobeNewswire) +7.85% -8.67%
Dec-02-24 07:30AM	Beyond Air Receives CE Mark in Europe for the LungFit PH System (GlobeNewswire)
Nov-26-24 07:30AM	NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board (GlobeNewswire) +22.16%
Nov-14-24 04:05PM	Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.71% -5.38%
Nov-11-24 04:05PM	Beyond Air Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.64%
07:00AM	Loading…
07:00AM	Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-08-24 07:06AM	Beyond Air Inc (XAIR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.86%
Oct-29-24 04:22PM	Beyond Air Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) +11.65% +8.78%
Oct-07-24 07:00AM	Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -5.45%
Oct-02-24 07:30AM	Beyond Air Partners with Healthcare Links to Expand Access to LungFit PH System Through Group Purchasing Organizations and Integrated Delivery Networks (GlobeNewswire) +10.57%
Sep-28-24 07:40AM	Beyond Air to sell 40.39M shares at 51c in private placement (TipRanks)
07:35AM	Beyond Air terminates loan, security agreements with Avenue Capital (TipRanks)
Sep-27-24 07:34AM	Beyond Air Provides LungFit PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed (GlobeNewswire)
07:32AM	Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital (GlobeNewswire)
07:30AM	Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Sep-23-24 08:00AM	Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire) -6.08%
Aug-06-24 04:05PM	Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -17.38%
Jul-31-24 04:15PM	Beyond Air Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia (GlobeNewswire) -5.16%
Jul-23-24 04:05PM	Beyond Air to Report First Fiscal Quarter 2025 Financial Results on August 6 (GlobeNewswire) +5.29%
Jul-16-24 04:05PM	Beyond Air To Participate in the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-10-24 09:55AM	Beyond Air (XAIR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +5.59%
Jun-26-24 08:01AM	Beyond Air, Inc. (NASDAQ:XAIR) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-25-24 10:31AM	Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock (InvestorPlace) -51.54%
08:28AM	Why Is Beyond Air (XAIR) Stock Down 22% Today? (InvestorPlace)
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-24-24 08:53PM	XAIR Stock Earnings: Beyond Air Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +8.06%
05:25PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Beyond Air Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-13-24 04:05PM	Beyond Air Appoints David Webster as Chief Commercial Officer (GlobeNewswire)
Jun-03-24 07:00AM	Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) (GlobeNewswire) -8.59%
May-23-24 04:09PM	Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -9.50%
May-01-24 07:00AM	Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
Mar-21-24 12:00PM	Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.84%
Mar-20-24 09:00AM	Beyond Air Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire)
Feb-13-24 08:51AM	Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript (Insider Monkey) -17.67%
Feb-12-24 04:05PM	Beyond Air Reports Financial Results for Third Quarter of Fiscal Year 2024 (GlobeNewswire) +14.97%
Jan-18-24 08:00AM	Beyond Air Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -5.02%
Dec-27-23 07:30AM	Beyond Cancer Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors (GlobeNewswire)
Dec-21-23 01:40AM	Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc (GuruFocus.com) +12.04%
Nov-15-23 04:05PM	Beyond Air To Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +23.57% -8.96%
Nov-14-23 10:00AM	Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Call Transcript (Insider Monkey) -31.03%
Nov-13-23 04:05PM	Beyond Air Reports Financial Results for Second Quarter of Fiscal Year 2024 (GlobeNewswire)
Nov-03-23 12:00PM	Beyond Cancer Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire) -6.91%
Oct-19-23 04:05PM	Beyond Air Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Oct-17-23 04:05PM	Beyond Air To Participate in the Truist Securities BioPharma Symposium (GlobeNewswire) +8.48% -6.17%
07:30AM	Beyond Cancer Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice (GlobeNewswire)
Oct-16-23 07:30AM	Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
07:00AM	Beyond Air Receives Innovative Technology Contract from Vizient for LungFit PH (GlobeNewswire)
Oct-04-23 07:30AM	Beyond Cancer Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-23 04:05PM	Beyond Air To Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -7.79%
Sep-27-23 09:00AM	Beyond Cancer to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting (GlobeNewswire)
Sep-18-23 04:05PM	Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder (GlobeNewswire) -7.95% +6.83%
Sep-07-23 07:30AM	Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region (GlobeNewswire)
Sep-06-23 07:00AM	Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-10-23 04:05PM	Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024 (GlobeNewswire)
Aug-08-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +13.35%
Aug-07-23 04:05PM	Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD) (GlobeNewswire)
Aug-01-23 04:05PM	Beyond Air® To Participate in BTIGs 2023 Virtual Biotechnology Conference (GlobeNewswire)
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +7.12%
Jul-24-23 04:05PM	Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -6.11% -5.42%
Jun-22-23 04:05PM	Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023 (GlobeNewswire) -18.84%
Jun-15-23 04:10PM	Beyond Air® Secures up to $40 Million Debt Financing (GlobeNewswire)
04:05PM	Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem (GlobeNewswire)
Jun-09-23 06:34AM	Daily Vickers Top Insider Picks for 06/09/2023 (Argus Research)
Jun-08-23 06:43AM	Daily Vickers Top Insider Picks for 06/08/2023 (Argus Research)
Jun-07-23 08:25AM	Daily Vickers Top Insider Picks for 06/07/2023 (Argus Research)
Jun-06-23 06:34AM	Daily Vickers Top Insider Picks for 06/06/2023 (Argus Research)
Jun-05-23 06:44AM	Daily Vickers Top Insider Picks for 06/05/2023 (Argus Research)
Jun-02-23 06:56AM	Daily Vickers Top Insider Picks for 06/02/2023 (Argus Research)
Jun-01-23 06:29AM	Daily Vickers Top Insider Picks for 06/01/2023 (Argus Research)
May-31-23 06:40AM	Daily Vickers Top Insider Picks for 05/31/2023 (Argus Research)
May-30-23 06:50AM	Daily Vickers Top Insider Picks for 05/30/2023 (Argus Research)
May-26-23 06:59AM	Daily Vickers Top Insider Picks for 05/26/2023 (Argus Research)
May-25-23 06:38AM	Daily Vickers Top Insider Picks for 05/25/2023 (Argus Research)
May-24-23 06:43AM	Daily Vickers Top Insider Picks for 05/24/2023 (Argus Research)

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carey Robert	Director	Mar 14 '25	Buy	0.25	1,000,000	250,050	4,076,864	Mar 17 08:15 AM
Gaul Michael A.	Chief Operating Officer	Feb 19 '25	Buy	0.38	6,000	2,294	94,150	Feb 21 05:00 PM
Carey Robert	Director	Sep 26 '24	Buy	0.50	1,476,626	744,662	1,476,626	Oct 01 09:58 PM
Lisi Steven A.	CEO and Chairman of the Board	Sep 26 '24	Buy	0.50	1,476,626	744,662	3,249,411	Oct 01 09:27 PM
Avniel Amir	Officer	Aug 22 '24	Proposed Sale	0.46	180,415	83,442		Aug 22 10:13 AM
Lisi Steven A.	CEO and Chairman of the Board	Aug 15 '24	Buy	0.37	50,000	18,340	1,772,785	Aug 19 06:06 AM
Lucera Erick	Director	Aug 14 '24	Buy	0.40	39,266	15,565	43,608	Aug 15 05:09 PM
Carey Robert	Director	Aug 14 '24	Buy	0.40	100,000	39,680	3,076,864	Aug 15 05:09 PM
Lisi Steven A.	CEO and Chairman of the Board	Aug 14 '24	Buy	0.39	100,000	38,640	1,722,785	Aug 15 05:09 PM

NVCT

Nuvectis Pharma Inc

XAIR

Beyond Air Inc

Upgrade your FINVIZ experience